TL;DR
This study used deep sequencing to analyze HIV breakthrough infections in participants receiving the broadly neutralizing antibody VRC01. They found that a significant portion of infections involved multiple viral lineages, and that recombination played a key role in the evolution of VRC01-resistant viruses, highlighting the need for multi-target strategies in HIV prevention.
What Problem Does This Paper Address?
HIV remains a major global health challenge. Broadly neutralizing antibodies (bNAbs) like VRC01 show promise for preventing HIV acquisition, but their effectiveness can be influenced by the diversity of the virus at the time of infection and how the virus evolves under antibody pressure. Previous studies, often using less sensitive sequencing methods, suggested that most HIV infections are initiated by a single "founder" virus. However, the authors hypothesized that more sensitive techniques might reveal a higher frequency of "multilineage infections" (where multiple distinct viral strains establish infection simultaneously). Understanding this initial viral diversity and subsequent viral evolution is crucial for designing effective bNAb-based prevention strategies, especially since HIV is known for its rapid evolution and ability to develop resistance. This paper aims to characterize the genetic diversity of breakthrough HIV infections in the context of VRC01-mediated prevention trials, specifically looking at the impact of VRC01 on the initial viral population and its subsequent evolution.
Methods
The researchers employed long-read deep sequencing to analyze viral genomes from participants in the Antibody Mediated Prevention (AMP) trials. This technique allowed them to generate a large number of sequences (over 100,000 total) from two key HIV genomic regions: gag-Δpol (GP) and rev-env-Δnef (REN). They then used sophisticated bioinformatics pipelines to:
- Classify sequences into Transmitted Founder Lineages (TFLs): This involved identifying distinct viral strains that successfully initiated infection.
- Detect multilineage infections: They defined this as the presence of more than one TFL within a participant's infection.
- Assess VRC01 sensitivity: They used pseudoviruses generated from representative viral sequences and measured their neutralization by VRC01 (quantified by IC80 values).
- Analyze viral recombination: They identified instances where different viral sequences exchanged genetic material.
- Estimate VRC01 concentrations: They used pharmacokinetic models to predict VRC01 levels at the estimated time of acquisition.
The use of deep sequencing is a key advancement here, offering much higher sensitivity than traditional methods for detecting rare viral variants.
Datasets
The study utilized data from the Antibody Mediated Prevention (AMP) trials, specifically:
- HVTN 703/HPTN 081 (Africa trial): Enrolled women at high risk of HIV acquisition.
- HVTN 704/HPTN 085 (Americas trial): Enrolled men who have sex with men and transgender individuals at high risk of HIV acquisition.
Participants in these trials received either VRC01 (at 10 mg/kg or 30 mg/kg doses) or a placebo, every eight weeks. The study analyzed viral sequences from 172 participants who acquired HIV during the trials.
Key Insights and Ideas
- The "acquisition bottleneck" might be wider than previously thought: While the study acknowledges that only a few virions typically establish infection, their high-sensitivity sequencing revealed a surprisingly high frequency of multilineage infections, suggesting that multiple founder viruses can indeed establish infection.
- VRC01's impact is complex: While VRC01 showed protective efficacy against susceptible strains, it didn't completely prevent infection by all strains. The antibody appears to exert selective pressure, influencing which viral variants persist and evolve.
- Recombination is a major player in viral evolution under pressure: The study highlights that recombination is not just a background process but actively contributes to HIV's ability to adapt and potentially escape antibody neutralization, especially in the context of multilineage infections.
- Timing and antibody levels matter: The data suggest that waning VRC01 levels between infusions might create windows of opportunity for co-acquisition of both sensitive and resistant viruses, and that lower predicted VRC01 concentrations at acquisition are associated with greater viral diversity.
Key Results
- High frequency of multilineage infections: Approximately 38% of participants in both the African and Americas cohorts acquired HIV with multiple transmitted founder lineages (TFLs), a rate higher than previously reported in studies using less sensitive methods.
- VRC01-discordant viruses are common: In 40% of multilineage infections, viruses with differing sensitivities to VRC01 (more than a 3-fold difference in IC80) were detected.
- Sensitive lineages decline under VRC01 pressure: In six participants who acquired both sensitive and resistant viruses, the sensitive lineages declined over time, while resistant ones persisted.
- Pervasive recombination: Recombination was observed in 63% of multilineage infections at the time of HIV diagnosis, and in one case, recombinant viruses preferentially inherited resistance mutations.
- Association between VRC01 levels and viral diversity: Lower predicted VRC01 concentrations at the time of acquisition were associated with greater intra-participant variance in viral neutralization sensitivity.
Limitations and Future Work
- Assumption of transmitted founder lineage: The study assumed that the viral sequence closest to the lineage-specific consensus best represented the transmitted founder. While supported by existing literature, they acknowledge this assumption could be violated by long periods between acquisition and sequencing or stochastic effects.
- Limited sample size for specific analyses: While the overall study is well-powered, some analyses, particularly those looking at specific evolutionary events or the impact of VRC01 concentration, involved smaller numbers of participants.
- Future directions: The authors suggest that future prevention strategies, similar to combination antiviral therapy, should target multiple viral antigens. Further research is needed to determine if combination bNAb therapy can reduce post-acquisition selection and to better define the role of recombination in HIV evolution under antibody pressure. The study also emphasizes the importance of maintaining consistently high monoclonal antibody levels in future prevention strategies.
Summary updated